Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.78
+0.15009.20%
Post-market: 1.920.1400+7.87%19:30 EDT
Volume:275.01K
Turnover:493.29K
Market Cap:87.48M
PE:-8.14
High:1.84
Open:1.67
Low:1.67
Close:1.63
52wk High:3.90
52wk Low:1.17
Shares:49.15M
Float Shares:43.50M
Volume Ratio:0.44
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2188
EPS(LYR):-0.2445
ROE:-25.56%
ROA:-16.41%
PB:2.35
PE(LYR):-7.28

Loading ...

3D Investment Partners Cuts Stake in Medicinova to 9.88% from 11.22%, Filing Shows

THOMSON REUTERS
·
Yesterday

3D Investment Partners Disposes of USD 1.73 Million MediciNova Common Shares

Reuters
·
Sep 30

MediciNova Extends Office Lease, Signals Long-Term Stability

TIPRANKS
·
Sep 29

Top Premarket Decliners

MT Newswires Live
·
Sep 28

MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment

Dow Jones
·
Sep 28

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

TIPRANKS
·
Sep 28

MediciNova Posts Phase 2 MN-001 Topline Data Showing Early Triglyceride Reduction in NAFLD Patients with Type 2 Diabetes

Reuters
·
Sep 28

Medicinova - Mn-001 Generally Safe and Well Tolerated with no Drug-Related Serious Adverse Events

THOMSON REUTERS
·
Sep 28

Medicinova - Mn-001 Shows Statistically Significant Serum Triglyceride Reduction at Week 4 Versus Placebo

THOMSON REUTERS
·
Sep 28

MediciNova Inc: at End of Study, Mean Body Weight Decreased by 4.91 Lb (2.28%) in Mn-001 Group and by 0.55 Lb (0.25%) in Placebo Group

THOMSON REUTERS
·
Sep 28

Medicinova Announces Topline Results from Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
Sep 28

Medicinova - Mn-001 Shows Statistically Significant Hdl Particle Increase at Week 24 Versus Placebo

THOMSON REUTERS
·
Sep 28

Buy Rating Reaffirmed on MediciNova as Advancing Pipeline and Upcoming Catalysts Support Unchanged $6 Price Target

TIPRANKS
·
Sep 26

MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

TIPRANKS
·
Sep 24

Medicinova - Topline Results from Double-Blind Portion Expected by End of 2026

THOMSON REUTERS
·
Sep 24

Medicinova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2B/3 Combat-ALS Trial of Mn-166 (Ibudilast)

THOMSON REUTERS
·
Sep 24

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewswire
·
Sep 24

NASDAQ Trade Halt Volatility Trading Pause at 09:33 Am

Reuters
·
Sep 18

Top Midday Gainers

MT Newswires Live
·
Sep 18

MediciNova Price Target Announced at $6.00/Share by Roth Capital

Dow Jones
·
Sep 17